Clinical Trial Update: Lorlatinib Continuation Study [Phase 4]

View source ↗

Summary

Pfizer's Lorlatinib continuation study (Phase 4) for Non-Small-Cell Lung Cancer is active but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lorbrena (lorlatinib)

Snippet

Sponsor: Pfizer | Conditions: Non-Small-Cell Lung Cancer, NSCLC | Phase 4 | Status: ACTIVE_NOT_RECRUITING